Quantum Genomics (Alternext - FR0011648971 - ALQGC) , a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, has published information on the total number of voting rights and number of shares comprising the share capital on august 23 rd 2015, in accordance with the provisions of article 223-16.
| Date | Number of shares | Number of voting rights | |
| August 23 rd 2015 | 6,927,334 | Theoretical | 8,187,326 |
| Exercisable (1) | 8,163,991 | ||
(1) The total number of voting rights is calculated based on the total shares minus shares without voting rights treasury shares. On august 23 rd 2015, 23,335 shares, representing a total of 23,335 voting rights, were registered under the liquidity contract assigned to the brokerage Invest Securities.
|
CONTACTS
Quantum Genomics Lionel Ségard Chairman & Chief Executive Officer 01 60 13 76 80 Quantum Genomics Marc Karako CFO – Investor Relations 01 60 13 76 84 marc.karako@quantum-genomics.com ACTUS finance et communication Jean-Michel Marmillon Press Relations 01 53 67 36 73 jmmarmillon@actus.fr |
|
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure. Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes. Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC). |
Information réglementée
Information relative au nombre total de droits de vote et d'actions composant le capital :
-
Full and original press release in PDF:
http://www.actusnews.com/documents_communiques/ACTUS-0-41035-QGC_shares-voting-rights_20150824_UK-VF.pdf
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer